Atezolizumab (anti-PD-L1)

Catalog No.A2004        Batch: A200408

Print

Technical Data

CAS No. 1380723-44-3
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99%
Protein concentration 4.4mg/ml
Endotoxin Level ＜1EU/mg

Biological Activity

Description Atezolizumab (anti-PD-L1) is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1. MW : 145 KD.
Targets
hPD-L1 [2]
(Cell-free assay)
0.4 nM(Kd)
In vitro

Treatment with single agent atezolizumab exerted a moderate anti-proliferative effect with ~ 30% cell death across all models.[1]
In vivo

when dual drug–loaded, core-shell nanoparticles (DLTPT) is used in combination with anti PD-L1, the tumor growth is inhibited, which induced immune response against tumor metastasis.[2]

Protocol (Only for Reference)

Cell Assay:

  • A MTT cell proliferation assays in human spheroids (A) or EPCAM+/CD45- cells (b), untreated or treated with selumetinib, atezolizumab, avelumab, or their combinations.
Animal Study:

  • Animal Models: 4T1 tumor–bearing BALB/c mice
    Dosages: 2.5 or 5 mg/kg
    Administration: i.v.
    Reference:[2]

Customer Product Validation

Selleck's Atezolizumab (anti-PD-L1) has been cited by 54 publications

[ Int Immunopharmacol, 2024, ] PubMed: 38442580
Pivotal role of myeloid-derived suppressor cells in infection-related tumor growth [ Cancer Med, 2024, 13(4):e6917] PubMed: 38457241
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN [ Research Square, 2024, 10.21203/rs.3.rs-3782509/v1] PubMed: none
Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy [ J Extracell Vesicles, 2023, 12(11):e12379] PubMed: 37974395
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [ Cell Death Dis, 2023, 14(9):636] PubMed: 37752152
YAP1 expression is associated with survival and immunosuppression in small cell lung cancer [ Cell Death Dis, 2023, 14(9):636] PubMed: 37752152
Synergistically Enhancing Immunotherapy Efficacy in Glioblastoma with Gold-Core Silica-Shell Nanoparticles and Radiation [ Int J Nanomedicine, 2023, 18:7677-7693] PubMed: 38111846
Analysis of the mechanisms regulating soluble PD-1 production and function in human NK cells [ Front Immunol, 2023, 14:1229341] PubMed: 37638041
ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma [ J Transl Med, 2023, 21(1):341] PubMed: 37217923
Self-assembled albumin nanoparticles induce pyroptosis for photodynamic/photothermal/immuno synergistic therapies in triple-negative breast cancer [ Front Immunol, 2023, 14:1173487] PubMed: 37342347

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.